TriangleDurvalumab 50 MG/ML (NCT07149363)
Durvalumab 50 MG/ML trial for Small Cell Lung Cancer (SCLC) (NCT07149363). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with completely removed small-cell lung cancer, pathologic T1–T2, N0–N1, M0. Surgery must be within 78 days of enrollment, with mediastinal lymph-node assessment. Previous systemic treatment for this cancer is excluded.
The idea: add durvalumab, which blocks PD-L1 immune signaling, to postoperative platinum/etoposide chemotherapy. Four three-week cycles combine durvalumab with cisplatin or carboplatin and etoposide. Nine four-week cycles of durvalumab alone follow. Researchers compare two-year disease-free survival with historical chemotherapy results.
This phase 2 study plans 65 patients. Alliance Foundation Trials sponsors six recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.